Application of mycocidin in preparation of mycobacterium abscessus and/or mycobacterium tuberculosis bacteriostatic agent

A technology of Mycobacterium tuberculosis and Mycobacterium, which is applied in the field of medicine

Pending Publication Date: 2022-04-01
BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +3
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although WHO has proposed three groups of drugs for the treatment of MDR, there are also some new drugs such as Bdq, etc., but there are still drug resistance problems

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mycocidin in preparation of mycobacterium abscessus and/or mycobacterium tuberculosis bacteriostatic agent
  • Application of mycocidin in preparation of mycobacterium abscessus and/or mycobacterium tuberculosis bacteriostatic agent
  • Application of mycocidin in preparation of mycobacterium abscessus and/or mycobacterium tuberculosis bacteriostatic agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Embodiment 1, TUB act on the in vitro inhibitory concentration of M.abscessus standard strain and MTB standard strain

[0044] 1.1. In vitro inhibitory concentration of TUB on M.abscessus standard strain

[0045] Preparation of the drug solution to be tested: Dissolve tubercidin (1, Tubercidin, 7-deazaadenosine, TUB, Shanghai Taosu Biochemical Technology Co., Ltd., T7004 / 69-33-0) with DMSO to obtain a TUB concentration of 32 μg / mL solution, which is the drug solution to be tested.

[0046] (1) Add 100 μl of Mueller Hinton (MH) medium (containing 5% OADC enrichment solution) to each well of a 96-well plate.

[0047] (2) After completing step (1), take the 96-well plate, add 100 μl of the drug solution to be tested (DMSO configuration) with a concentration of 32 μg / mL in the last column, mix well, suck out 100 μl and add it to the 11th column, and serially dilute After reaching the second column, draw out 100 μl and discard it, and the first column does not contain drug...

Embodiment 2

[0067] Embodiment 2, TUB act on the in vitro inhibitory concentration of M.abscessus clinical strain and MTB clinical strain

[0068] 2.1 In vitro inhibitory concentration of TUB on M.abscessus clinical strains

[0069] Collect 18 M.abscessus clinical strains (clinical isolates, stored in the Beijing Major Disease Clinical Data and Sample Resource Bank of Beijing Chest Hospital Affiliated to Capital Medical University - Tuberculosis Bank, in the literature Yu X, Gao X, Li C, et al .In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China.Antimicrob Agents Chemother. 2019; 63(8):e00031-19.Published 2019Jul 25.doi:10.1128 / AAC.00031-19. per publication), Strain bacterial strain is done 2 repetitions, set up positive control (no drug-dosing group) and negative control (blank culture medium group without adding bacteria) simultaneously, in vitro MIC experiment (specific operation method is the same as embodiment 1) detects TUB ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, in particular to application of mycocidin in preparation of a bacteriostatic agent for mycobacterium abscessus and / or mycobacterium tuberculosis. The invention firstly discloses the application of the mycocidin in preparation of the bacteriostatic agent for the mycobacterium abscessus and / or the mycobacterium tuberculosis, and further discloses the bacteriostatic agent for inhibiting the mycobacterium abscessus and / or the mycobacterium tuberculosis, and the active ingredient of the bacteriostatic agent is the mycocidin. The mycocide has good bactericidal activity when independently acting on mycobacterium abscessus and / or independently acting on mycobacterium tuberculosis, can be used for treating the tuberculosis, has a remarkable inhibition effect on the mycobacterium abscessus and / or the mycobacterium tuberculosis, and has important significance in preventing and treating the tuberculosis.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of tubercidin in the preparation of bacteriostatic agents for Mycobacterium abscessus and / or Mycobacterium tuberculosis. Background technique [0002] Tuberculin (1, Tubercidin, 7-deazaadenosine, TUB), the molecular formula is C 11 h 14 N 4 o 4 , the molecular weight is 266.25, and its structural formula is as follows: [0003] [0004] Tubercidin is a nucleoside antibiotic isolated from the fermentation broth of Streptomyces tubericidus. It is a pyrrolidine nucleoside natural product and one of the earliest discovered 7-deazapurine nucleoside natural products. The structural difference from adenosine is only the change of N-7 to C-7. Tuberculin is metabolized into 5'-tuberculin triphosphate in the cell through the nucleoside transport mechanism, and acts as an analog of adenosine triphosphate (ATP) during the synthesis of DNA and RNA in the cell, inhibiting DNA A...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): A61K31/7064A61P31/04A61P31/06
Inventor王桂荣李浩黄海荣孙晴
OwnerBEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV